Eloxx制药近日正式宣布，其用于治疗无义突变Alport综合征的在研药物Exaluren，已在EXACT二期B临床试验中完成首批患者给药。这一里程碑式的进展，标志着该潜在疗法在临床开发道路上迈出了坚实且重要的一步。Exaluren作为一种新型的读出机制药物，旨在通过诱导核糖体通读提前出现的终止密码子，从而恢复全长功能性蛋白质的生成。此次研究的启动，不仅为饱受这种罕见遗传性肾病困扰的患者群体带来了新的希望，也进一步验证了公司在该领域的专业布局与科研实力。
Eloxx制药近日正式宣布，其用于治疗无义突变Alport综合征的在研药物Exaluren，已在EXACT二期B临床试验中完成首批患者给药。这一里程碑式的进展，标志着该潜在疗法在临床开发道路上迈出了坚实且重要的一步。Exaluren作为一种新型的读出机制药物，旨在通过诱导核糖体通读提前出现的终止密码子，从而恢复全长功能性蛋白质的生成。此次研究的启动，不仅为饱受这种罕见遗传性肾病困扰的患者群体带来了新的希望，也进一步验证了公司在该领域的专业布局与科研实力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.